Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...

Regulation of Nuclear Protein Sorting

Regulation of Nuclear Protein Sorting

Nuclear protein sorting regulates nucleus composition and gene expression, crucial for determining the fate of a eukaryotic cell. Hence, the entry and exit of molecules across the nuclear envelope is a tightly controlled process. Nuclear protein sorting can be inhibited by one of the following ways: 1) masking cargo signal sequences, 2) modifying the nuclear receptor's affinity for cargo, 3) controlling the nuclear pore size, 4) retaining the cargo during its transit to the cytosol or the...

Allosteric Proteins-ATCase

Allosteric Proteins-ATCase

Binding sites linkages can regulate a protein's function. For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis pathway,...

Calmodulin-dependent Signaling

Calmodulin-dependent Signaling

Calmodulin (CaM) is a calcium-binding protein in eukaryotes that controls various calcium-regulated cellular processes. It has four calcium-binding sites that bind calcium to form the calcium-calmodulin ( Ca2+-CaM) complex. GPCR stimulation increases the calcium levels in the cells that bind to CaM and induces a conformational change.
The Ca2+-CaM complex does not have enzymatic activity by itself. Instead, the complex binds downstream target proteins, including membrane proteins or enzymes,...

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Incidence and risk factors of <i>C. trachomatis</i>, <i>N. gonorrhoeae</i> and syphilis among a cohort of urban Canadian gay, bisexual and other men who have sex with men, 2017-2023: informing the potential impact of doxycycline prophylaxis.

BMJ open·2026

Same author

Interventions to improve adherence among patients prescribed statins for primary prevention of cardiovascular diseases: A systematic review and meta-analysis.

European journal of preventive cardiology·2026

Same author

Transfusion reactions reported to the Québec haemovigilance system between 2005 and 2022: A comparison of paediatric and adult recipients.

British journal of haematology·2026

Same author

Targeting excessive cholesterol deposition alleviates secondary lymphoedema.

Nature·2026

Same author

CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne·2025

Same author

Canadian guideline on HIV pre- and postexposure prophylaxis: 2025 update.

CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne·2025

Search research articles

Related Experiment Video

Updated: Jul 3, 2026

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9

Published on: August 28, 2018

Molecular basis of PCSK9 function.

Gilles Lambert¹, Francesca Charlton, Kerry-Anne Rye

¹The Heart Research Institute, Camperdown, NSW 2050, Australia. lambertg@hri.org.au

Atherosclerosis

|July 25, 2008

Summary

This summary is machine-generated.

Proprotein Convertase Subtilisin Kexin type 9 (PCSK9) binds the LDL receptor (LDLr) for degradation, offering a target for lowering cholesterol. Understanding PCSK9

More Related Videos

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

Related Experiment Videos

Last Updated: Jul 3, 2026

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9

Published on: August 28, 2018

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

Area of Science:

Biochemistry
Molecular Biology
Genetics

Background:

Proprotein Convertase Subtilisin Kexin type 9 (PCSK9) is a key regulator of LDL cholesterol metabolism.
PCSK9 functions as a chaperone protein that binds to the LDL receptor (LDLr).
This interaction targets the LDLr for lysosomal degradation, increasing plasma LDL cholesterol levels.

Purpose of the Study:

To review the functional significance of PCSK9.
To explore PCSK9's role in LDL receptor regulation.
To summarize PCSK9's potential as a prognostic tool and drug target.

Main Methods:

Review of studies published before May 2008.
Analysis of site-directed mutagenesis data.
Examination of PCSK9 crystal structure reports.
Investigation of naturally occurring PCSK9 mutants.

Main Results:

PCSK9 acts as a chaperone, binding LDLr and targeting it for lysosomal degradation.
The enzymatic activity of PCSK9 is not essential for LDLr degradation but for its own processing.
Naturally occurring PCSK9 mutants are associated with hyper- or hypocholesterolemia.

Conclusions:

PCSK9 is a genetically validated target for lowering plasma LDL cholesterol.
Understanding PCSK9's mechanism provides insights into cholesterol regulation.
PCSK9 holds promise as a therapeutic target and prognostic marker.